RE:RE:RE:RE:RE:RE:Egrifta Patent Situationpalinc2000 wrote: All biotechs in the world talk and write in a promotional way of potential drugs in their pipeline ....That is how they fund themselves ,that 's how they keep in business by selling dreams even though only one in hundreds eventually make it to market
From what I gleaned from the cc the costs to getting this drug into a small number of patients within 2/3 years looks very limited. And I expect that those early patients are going to tell us a lot about the effectiveness of this drug. I think they are risking very little on this dream.
It seems to be focused exclusively on the long term value of the company, something thats poorly covered atm.